YIPF6

Across TCGA pan-cancer cohorts, YIPF6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated YIPF6 data layer compared with 21 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher YIPF6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated YIPF6 expression acts as an unfavorable survival marker.

PRAD, BRCA, and UCEC are the cancer types where YIPF6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	OS	Median	All	0.080	0.990	<.001	12	view →
BRCA	OS	Median	All	0.789	0.963	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

YIPF6–PRAD (OS)

Open the PRAD breakdown →